Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Prosetta Biosciences Inc. maintains a portfolio in the Biotechnology & Pharmaceuticals technology area with 3 pending office actions. These actions are distributed across 2 distinct examiners and 2 distinct art units, suggesting a diversified examination path within the USPTO. The presence of multiple art units indicates that the company's research may touch upon different specialized sub-fields within the broader biotechnology sector.
Examiner RICCI, CRAIG D is identified as the busiest examiner for the company, currently overseeing a portion of the pending workload. This concentration means that some of the 3 pending matters are being evaluated by a single individual, which may streamline communication for those specific applications. With the busiest examiner pending count at 2, the company must balance the specific preferences of RICCI, CRAIG D against the requirements of other personnel. Navigating the distinct art units further necessitates a flexible approach to prosecution, as different departments may have varying interpretations of patentability criteria.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RICCI, CRAIG D | 2 | 53.7% | +52.6% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18760472 | 2-Thioxothiazolidine-4-One Derivatives And Their Uses | RICCI, CRAIG D | — |
| 18583535 | Phenothiazinyl Compounds and Uses | RICCI, CRAIG D | — |
| Art Unit | Apps |
|---|---|
| 1611 | 2 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18760472 | 2-Thioxothiazolidine-4-One Derivatives And Their Uses | RICCI, CRAIG D | 1611 | §102 | Non-Final OA | — | Pending | Jul 01, 2024 |
| 18662524 | Isoquinoline Derivatives, Methods of Synthesis and Uses Thereof | SHTERENGARTS, SAMANTHA L | 1623 | §102DP | Non-Final OA | — | Pending | May 13, 2024 |
| 18583535 | Phenothiazinyl Compounds and Uses | RICCI, CRAIG D | 1611 | §102DP | Non-Final OA | — | Pending | Feb 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialProsetta Biosciences Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Craig D Ricci has the most, with 2 of Prosetta Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
